lifestyle.celebhomes.net
Home
Sample Page
Author:
Entrada Therapeutics, Inc.
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
May 6, 2026
Entrada Therapeutics to Present at Upcoming Investor Conferences
February 4, 2026